The influence of early intervention in acute @entity583 on long-term mortality and morbidity as assessed in the G  teborg XXXX trial.

@entity1 @entity1406 @entity951 @entity1188 @entity158 @entity583
The mortality and morbidity were assessed during a 2-year follow-up in an acute intervention trial in suspected acute @entity583 with @entity1406 (a selective beta 1-blocker). On admission to the trial, the 1395 participating @entity1 were randomly allocated to @entity1406 or placebo for 3 months. Thereafter, if there was no contraindication, @entity1 with @entity1188 and/or @entity951 were continued on @entity1406 for 2 years. A lower mortality was observed after 3 months in @entity1 randomised to @entity1406 . The difference remained after 2 years. The difference in 2-year mortality rate was restricted to @entity1 randomised early after onset of @entity158 . Late @entity1188 was observed more often in the placebo group during the first 3 months. When the two groups thereafter were treated similarly, the difference successively declined and did not remain after 2 years. A similar incidence of @entity951 was observed in the two groups at each check up. During the early recovery period, more @entity1 in the @entity1406 group returned to work. No such difference was observed later on.
